COVISHIELD phase 2, 3 trials get DCGI nod

News: Drugs Controller General of India(DCGI) has given approval to Serum Institute of India(SII) to conduct Phase II+III clinical trials of Oxford University AstraZeneca COVID-19 vaccine(COVISHIELD). Facts: COVISHIELD: The Oxford vaccine “AZD1222” is being called Covishield in India. The Serum Institute of India(SII) has entered into a manufacturing partnership with biopharma major AstraZeneca to produce… Continue reading COVISHIELD phase 2, 3 trials get DCGI nod